Article Sidebar
Published:
Oct 2, 2017Article Details
Copyright remains in the Author’s name. The work is licensed under a Creative Commons Attribution - Noncommercial Works License. Authors are required to complete and sign an Author Agreement form that outlines Author and Publisher rights and terms of publication. The Agreement form should be uploaded along with other submissions files and any submission will be considered incomplete without it [forthcoming].
Material submitted for publication in the SAMJ is accepted provided it has not been published or submitted for publication elsewhere. Please inform the editorial team if the main findings of your paper have been presented at a conference and published in abstract form, to avoid copyright infringement. The SAMJ does not hold itself responsible for statements made by the authors.
Previously published images
If an image/figure has been previously published, permission to reproduce or alter it must be obtained by the authors from the original publisher and the figure legend must give full credit to the original source. This credit should be accompanied by a letter indicating that permission to reproduce the image has been granted to the author/s. This letter should be uploaded as a supplementary file during submission.
Main Article Content
The maximum medical aid price programme: A review of the concept and of its ability to reduce expenditure on medicines
Abstract
Medicine prices in South Africa have increased significantly in recent years. Furthermore, a consideration of expenditure on medicines by medical schemes shows that this component of health care costs had grown to 26,1% in 1988, which is high by comparison with other Western economies. The use of generic medicines offers one possible solution to rising expenditure. For savings to be optimised, however, generics need to be used on a planned and structured basis. The maximum medical aid price (MMAP) system of the Pharmaceutical Society of South Africa provides such a programme.
MMAP is a programme through which certain medical schemes elect to pay only a specified maximum price for offpatent products that have generic equivalents. Although MMAP does not require substitution by generic medicines, it does have the effect of encouraging their use.
Two case studies measuring the savings that can be achieved through adoption of MMAP by medical schemes are reviewed. Although they differ in their respective methodologies, their results are consistent and show that savings of about 9,3% were possible in 1989. Medical schemes with higher proportions of older members tend to show greater savings. The studies also show that the potential for achieving savings through the use of MMAP increases with the passage of time.
